JP2009535033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535033A5 JP2009535033A5 JP2009507847A JP2009507847A JP2009535033A5 JP 2009535033 A5 JP2009535033 A5 JP 2009535033A5 JP 2009507847 A JP2009507847 A JP 2009507847A JP 2009507847 A JP2009507847 A JP 2009507847A JP 2009535033 A5 JP2009535033 A5 JP 2009535033A5
- Authority
- JP
- Japan
- Prior art keywords
- tdgf3
- polynucleotide
- sample
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000835739 Homo sapiens Putative teratocarcinoma-derived growth factor 3 Proteins 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 127
- 102100026407 Putative teratocarcinoma-derived growth factor 3 Human genes 0.000 claims description 97
- 108091033319 polynucleotide Proteins 0.000 claims description 87
- 102000040430 polynucleotide Human genes 0.000 claims description 87
- 239000002157 polynucleotide Substances 0.000 claims description 87
- 239000000523 sample Substances 0.000 claims description 63
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 32
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims description 31
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims description 24
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 23
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 108091026890 Coding region Proteins 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000013610 patient sample Substances 0.000 claims description 12
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000009175 antibody therapy Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000711 cancerogenic effect Effects 0.000 claims description 4
- 231100000315 carcinogenic Toxicity 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000010307 cell transformation Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 210000004988 splenocyte Anatomy 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000002726 cyst fluid Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 101100369075 Homo sapiens TDGF1 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 101150071658 TDGF1 gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79580706P | 2006-04-28 | 2006-04-28 | |
| PCT/US2007/010399 WO2007127461A2 (en) | 2006-04-28 | 2007-04-30 | Composition and methods for the detection of cripto-3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535033A JP2009535033A (ja) | 2009-10-01 |
| JP2009535033A5 true JP2009535033A5 (enExample) | 2010-07-01 |
Family
ID=38656259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507847A Withdrawn JP2009535033A (ja) | 2006-04-28 | 2007-04-30 | Ｃｒｉｐｔｏ−３の検出のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100041032A1 (enExample) |
| EP (1) | EP2021510A2 (enExample) |
| JP (1) | JP2009535033A (enExample) |
| CN (1) | CN101479391A (enExample) |
| AU (1) | AU2007243181A1 (enExample) |
| CA (1) | CA2650379A1 (enExample) |
| WO (1) | WO2007127461A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK14432003A3 (sk) * | 2001-04-26 | 2004-07-07 | Biogen, Inc. | Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| EP2311880A3 (en) * | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| GB0020953D0 (en) * | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| AU9272401A (en) * | 2000-09-18 | 2002-03-26 | Biogen Inc | Cripto mutant and uses thereof |
| JP2005520566A (ja) * | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ特異的抗体 |
-
2007
- 2007-04-30 US US12/298,875 patent/US20100041032A1/en not_active Abandoned
- 2007-04-30 AU AU2007243181A patent/AU2007243181A1/en not_active Abandoned
- 2007-04-30 WO PCT/US2007/010399 patent/WO2007127461A2/en not_active Ceased
- 2007-04-30 EP EP07776467A patent/EP2021510A2/en not_active Withdrawn
- 2007-04-30 CN CNA2007800243961A patent/CN101479391A/zh active Pending
- 2007-04-30 CA CA002650379A patent/CA2650379A1/en not_active Abandoned
- 2007-04-30 JP JP2009507847A patent/JP2009535033A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5091163B2 (ja) | 癌またはその素因の早期検出のための方法およびキット | |
| EP2848700B1 (en) | Markers for endometrial cancer | |
| US20130065789A1 (en) | Compositions and methods for classifying lung cancer and prognosing lung cancer survival | |
| CA2882759A1 (en) | Detection of the ntrk1-mprip gene fusion for cancer diagnosis | |
| KR101997320B1 (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| KR101359851B1 (ko) | 간세포암종의 예후 진단용 단일 염기 다형성 | |
| JP2009535033A5 (enExample) | ||
| US20210371520A1 (en) | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) | |
| KR20170124683A (ko) | 담도암 진단용 신규 바이오마커로서의 융합 유전자 및 융합 단백질 | |
| KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
| JP7150018B2 (ja) | 新規なｃｉｐ２ａバリアント及びその使用 | |
| KR102171189B1 (ko) | 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 활용 | |
| US20070264651A1 (en) | Methods, compositions, and kits for the detection and monitoring of kidney cancer | |
| US20070281895A1 (en) | Molecular Marker | |
| WO2008030559A2 (en) | Methods, compositions, and kits for the detection and monitoring of colon cancer | |
| KR101054953B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 ｓｎｘ１４, 그를 포함하는 키트 | |
| WO2015194524A1 (ja) | Ｂ前駆細胞性急性リンパ芽球性白血病新規キメラ遺伝子 | |
| EP4317458A1 (en) | Follicular thyroid cancer-specific marker | |
| WO2014185466A1 (ja) | 膵がんの予後評価方法 | |
| KR101683961B1 (ko) | 방광암 재발 진단 마커 | |
| JP5467256B2 (ja) | 消化器癌検出用血清腫瘍マーカー、消化器癌検出キット、および消化器癌検出方法 | |
| KR20060013868A (ko) | 위암 유전자 마커 및 이를 이용한 위암 진단킷트 | |
| KR101054951B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 ｃａｐｎ１２, 그를 포함하는 키트 | |
| KR20190037071A (ko) | 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도 | |
| US20120040366A1 (en) | Compositions, methods and uses for disease diagnosis |